Annual Cash & Cash Equivalents
$2.85 B
+$2.44 B+585.82%
31 December 2023
Summary:
Pfizer annual cash & cash equivalents is currently $2.85 billion, with the most recent change of +$2.44 billion (+585.82%) on 31 December 2023. During the last 3 years, it has risen by +$1.07 billion (+59.74%). PFE annual cash & cash equivalents is now -71.70% below its all-time high of $10.08 billion, reached on 31 December 2012.PFE Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Cash And Cash Equivalents
$1.09 B
+$40.00 M+3.80%
30 September 2024
Summary:
Pfizer quarterly cash and cash equivalents is currently $1.09 billion, with the most recent change of +$40.00 million (+3.80%) on 30 September 2024. Over the past year, it has dropped by -$2.06 billion (-65.31%). PFE quarterly cash and cash equivalents is now -89.17% below its all-time high of $10.08 billion, reached on 31 December 2012.PFE Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
PFE Cash And Cash Equivalents Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +585.8% | -65.3% |
| 3 y3 years | +59.7% | -44.5% |
| 5 y5 years | +150.5% | -60.8% |
PFE Cash And Cash Equivalents High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | at high | +585.8% | -65.3% | +162.5% |
| 5 y | 5 years | at high | +585.8% | -65.3% | +162.5% |
| alltime | all time | -71.7% | +615.8% | -89.2% | +471.7% |
Pfizer Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $1.09 B(+3.8%) |
| June 2024 | - | $1.05 B(+46.3%) |
| Mar 2024 | - | $719.00 M(-74.8%) |
| Dec 2023 | $2.85 B(+585.8%) | $2.85 B(-9.4%) |
| Sept 2023 | - | $3.15 B(+19.6%) |
| June 2023 | - | $2.63 B(+21.5%) |
| Mar 2023 | - | $2.17 B(+420.7%) |
| Dec 2022 | $416.00 M(-78.6%) | $416.00 M(-68.0%) |
| Sept 2022 | - | $1.30 B(-27.1%) |
| June 2022 | - | $1.78 B(-27.9%) |
| Mar 2022 | - | $2.47 B(+27.1%) |
| Dec 2021 | $1.94 B(+8.8%) | $1.94 B(-1.1%) |
| Sept 2021 | - | $1.97 B(-17.1%) |
| June 2021 | - | $2.37 B(+34.2%) |
| Mar 2021 | - | $1.77 B(-1.0%) |
| Dec 2020 | $1.79 B(+59.3%) | $1.79 B(+12.5%) |
| Sept 2020 | - | $1.59 B(-11.9%) |
| June 2020 | - | $1.80 B(-16.3%) |
| Mar 2020 | - | $2.15 B(+91.9%) |
| Dec 2019 | $1.12 B(-1.6%) | $1.12 B(-59.7%) |
| Sept 2019 | - | $2.79 B(+56.1%) |
| June 2019 | - | $1.78 B(-7.9%) |
| Mar 2019 | - | $1.94 B(+70.1%) |
| Dec 2018 | $1.14 B(-15.1%) | $1.14 B(-68.0%) |
| Sept 2018 | - | $3.56 B(+31.6%) |
| June 2018 | - | $2.70 B(+17.5%) |
| Mar 2018 | - | $2.30 B(+71.5%) |
| Dec 2017 | $1.34 B(-48.3%) | $1.34 B(-51.7%) |
| Sept 2017 | - | $2.78 B(+7.5%) |
| June 2017 | - | $2.58 B(-36.3%) |
| Mar 2017 | - | $4.06 B(+56.3%) |
| Dec 2016 | $2.60 B(-28.7%) | $2.60 B(+23.9%) |
| Sept 2016 | - | $2.09 B(-38.6%) |
| June 2016 | - | $3.41 B(+33.2%) |
| Mar 2016 | - | $2.56 B(-29.7%) |
| Dec 2015 | $3.64 B(+8.9%) | $3.64 B(+17.5%) |
| Sept 2015 | - | $3.10 B(-15.6%) |
| June 2015 | - | $3.67 B(+3.0%) |
| Mar 2015 | - | $3.56 B(+6.6%) |
| Dec 2014 | $3.34 B(+53.1%) | $3.34 B(+37.2%) |
| Sept 2014 | - | $2.44 B(-28.4%) |
| June 2014 | - | $3.41 B(+19.0%) |
| Mar 2014 | - | $2.86 B(+31.1%) |
| Dec 2013 | $2.18 B(-78.3%) | $2.18 B(+6.4%) |
| Sept 2013 | - | $2.05 B(-15.8%) |
| June 2013 | - | $2.44 B(+14.2%) |
| Mar 2013 | - | $2.13 B(-78.8%) |
| Dec 2012 | $10.08 B(+216.8%) | $10.08 B(+123.7%) |
| Sept 2012 | - | $4.51 B(+48.7%) |
| June 2012 | - | $3.03 B(+3.3%) |
| Mar 2012 | - | $2.93 B(-7.8%) |
| Dec 2011 | $3.18 B(+83.4%) | $3.18 B(-14.1%) |
| Sept 2011 | - | $3.71 B(+19.7%) |
| June 2011 | - | $3.10 B(+324.1%) |
| Mar 2011 | - | $730.00 M(-57.9%) |
| Dec 2010 | $1.74 B(-12.3%) | $1.74 B(-20.3%) |
| Sept 2010 | - | $2.18 B(+15.9%) |
| June 2010 | - | $1.88 B(+6.7%) |
| Mar 2010 | - | $1.76 B(-11.1%) |
| Dec 2009 | $1.98 B(-6.8%) | $1.98 B(-53.3%) |
| Sept 2009 | - | $4.23 B(+88.7%) |
| June 2009 | - | $2.24 B(+80.0%) |
| Mar 2009 | - | $1.25 B(-41.2%) |
| Dec 2008 | $2.12 B(-37.7%) | $2.12 B(+67.7%) |
| Sept 2008 | - | $1.26 B(+54.3%) |
| June 2008 | - | $820.00 M(-59.3%) |
| Mar 2008 | - | $2.01 B(-40.9%) |
| Dec 2007 | $3.41 B(+86.4%) | $3.41 B(+30.4%) |
| Sept 2007 | - | $2.61 B(+22.1%) |
| June 2007 | - | $2.14 B(-14.2%) |
| Mar 2007 | - | $2.49 B(+36.4%) |
| Dec 2006 | $1.83 B | $1.83 B(+55.2%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2006 | - | $1.18 B(-38.7%) |
| June 2006 | - | $1.92 B(-33.0%) |
| Mar 2006 | - | $2.87 B(+27.7%) |
| Dec 2005 | $2.25 B(+24.3%) | $2.25 B(+134.3%) |
| Sept 2005 | - | $959.00 M(-24.8%) |
| June 2005 | - | $1.28 B(-13.6%) |
| Mar 2005 | - | $1.48 B(-18.4%) |
| Dec 2004 | $1.81 B(+18.9%) | $1.81 B(-3.0%) |
| Sept 2004 | - | $1.86 B(+185.9%) |
| June 2004 | - | $652.00 M(-32.4%) |
| Mar 2004 | - | $965.00 M(-36.5%) |
| Dec 2003 | $1.52 B(-19.1%) | $1.52 B(-5.6%) |
| Sept 2003 | - | $1.61 B(-26.5%) |
| June 2003 | - | $2.19 B(+5.9%) |
| Mar 2003 | - | $2.07 B(+10.1%) |
| Dec 2002 | $1.88 B(+81.3%) | $1.88 B(+5.9%) |
| Sept 2002 | - | $1.77 B(+48.3%) |
| June 2002 | - | $1.20 B(-10.2%) |
| Mar 2002 | - | $1.33 B(+28.6%) |
| Dec 2001 | $1.04 B(-5.7%) | $1.04 B(-45.4%) |
| Sept 2001 | - | $1.90 B(+46.6%) |
| June 2001 | - | $1.29 B(+10.1%) |
| Mar 2001 | - | $1.18 B(+7.0%) |
| Dec 2000 | $1.10 B(-53.4%) | $1.10 B(-18.0%) |
| Sept 2000 | - | $1.34 B(-15.7%) |
| June 2000 | - | $1.59 B(+732.5%) |
| Mar 2000 | - | $191.00 M(-91.9%) |
| Dec 1999 | $2.36 B(+51.9%) | $2.36 B(+150.3%) |
| Sept 1999 | - | $942.00 M(-23.0%) |
| June 1999 | - | $1.22 B(+4.9%) |
| Mar 1999 | - | $1.17 B(-24.9%) |
| Dec 1998 | $1.55 B(+77.0%) | $1.55 B(-43.0%) |
| Sept 1998 | - | $2.72 B(+150.0%) |
| June 1998 | - | $1.09 B(+3.4%) |
| Mar 1998 | - | $1.05 B(+20.1%) |
| Dec 1997 | $877.00 M(-23.7%) | $877.00 M(-26.3%) |
| Sept 1997 | - | $1.19 B(-21.4%) |
| June 1997 | - | $1.51 B(+23.1%) |
| Mar 1997 | - | $1.23 B(+7.0%) |
| Dec 1996 | $1.15 B(+185.1%) | $1.15 B(+9.9%) |
| Sept 1996 | - | $1.05 B(+20.2%) |
| June 1996 | - | $870.00 M(+6.4%) |
| Mar 1996 | - | $818.00 M(+102.8%) |
| Dec 1995 | $403.30 M(-72.3%) | $403.30 M(-45.0%) |
| Sept 1995 | - | $733.60 M(+17.6%) |
| June 1995 | - | $623.60 M(-35.5%) |
| Mar 1995 | - | $967.00 M(-33.7%) |
| Dec 1994 | $1.46 B(+100.0%) | $1.46 B(+63.1%) |
| Sept 1994 | - | $894.20 M(+11.2%) |
| June 1994 | - | $804.10 M(+0.9%) |
| Mar 1994 | - | $796.80 M(+9.2%) |
| Dec 1993 | $729.40 M(-42.0%) | $729.40 M(-40.6%) |
| Sept 1993 | - | $1.23 B(+5.9%) |
| June 1993 | - | $1.16 B(+13.8%) |
| Mar 1993 | - | $1.02 B(-18.9%) |
| Dec 1992 | $1.26 B(-4.6%) | $1.26 B(+16.4%) |
| Sept 1992 | - | $1.08 B(+14.6%) |
| June 1992 | - | $941.90 M(-11.6%) |
| Mar 1992 | - | $1.07 B(-19.1%) |
| Dec 1991 | $1.32 B(+51.4%) | $1.32 B(+95.6%) |
| Sept 1991 | - | $673.50 M(-0.3%) |
| June 1991 | - | $675.80 M(+11.0%) |
| Mar 1991 | - | $608.90 M(-30.0%) |
| Dec 1990 | $870.30 M(+5.4%) | $870.30 M(+182.7%) |
| Sept 1990 | - | $307.90 M(-22.9%) |
| June 1990 | - | $399.10 M(+2.6%) |
| Mar 1990 | - | $388.90 M(-52.9%) |
| Dec 1989 | $825.40 M(+2.2%) | $825.40 M(+2.2%) |
| Dec 1988 | $807.50 M(-21.7%) | $807.50 M(-21.7%) |
| Dec 1987 | $1.03 B(+158.7%) | $1.03 B(+158.7%) |
| Dec 1986 | $398.60 M(-3.4%) | $398.60 M(-3.4%) |
| Dec 1985 | $412.60 M(-53.2%) | $412.60 M(-53.2%) |
| Dec 1984 | $880.90 M | $880.90 M |
FAQ
- What is Pfizer annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Pfizer?
- What is Pfizer annual cash & cash equivalents year-on-year change?
- What is Pfizer quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Pfizer?
- What is Pfizer quarterly cash and cash equivalents year-on-year change?
What is Pfizer annual cash & cash equivalents?
The current annual cash & cash equivalents of PFE is $2.85 B
What is the all time high annual cash & cash equivalents for Pfizer?
Pfizer all-time high annual cash & cash equivalents is $10.08 B
What is Pfizer annual cash & cash equivalents year-on-year change?
Over the past year, PFE annual cash & cash equivalents has changed by +$2.44 B (+585.82%)
What is Pfizer quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of PFE is $1.09 B
What is the all time high quarterly cash and cash equivalents for Pfizer?
Pfizer all-time high quarterly cash and cash equivalents is $10.08 B
What is Pfizer quarterly cash and cash equivalents year-on-year change?
Over the past year, PFE quarterly cash and cash equivalents has changed by -$2.06 B (-65.31%)